Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Liabilities and Shareholders Equity: 2020-2022

Historic Liabilities and Shareholders Equity for Candel Therapeutics (CADL) over the last 3 years, with Dec 2022 value amounting to $77.7 million.

  • Candel Therapeutics' Liabilities and Shareholders Equity fell 41.11% to $50.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $253.7 million, marking a year-over-year decrease of 31.26%. This contributed to the annual value of $77.7 million for FY2022, which is 12.91% down from last year.
  • Candel Therapeutics' Liabilities and Shareholders Equity amounted to $77.7 million in FY2022, which was down 12.91% from $89.2 million recorded in FY2021.
  • Over the past 5 years, Candel Therapeutics' Liabilities and Shareholders Equity peaked at $89.2 million during FY2021, and registered a low of $38.3 million during FY2020.
  • In the last 3 years, Candel Therapeutics' Liabilities and Shareholders Equity had a median value of $77.7 million in 2022 and averaged $68.4 million.
  • In the last 5 years, Candel Therapeutics' Liabilities and Shareholders Equity spiked by 133.02% in 2021 and then fell by 12.91% in 2022.
  • Candel Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $38.3 million in 2020, then spiked by 133.02% to $89.2 million in 2021, then fell by 12.91% to $77.7 million in 2022.